Siperstein Allan, Berber Eren, Barbosa German F, Tsinberg Michael, Greene Andrew B, Mitchell Jamie, Milas Mira
Endocrine and Metabolism Institute, Section of Endocrine Surgery, The Cleveland Clinic, Cleveland, Ohio 44195, USA.
Ann Surg. 2008 Sep;248(3):420-8. doi: 10.1097/SLA.0b013e3181859f71.
The aim of this study was to determine the success of limited neck exploration (LE) for primary hyperparathyroidism (1 degrees HPT).
Between 1999 and 2007, 1407 patients with hyperparathyroidism underwent bilateral neck exploration (BE). Of these, 1158 patients with first-time sporadic 1 degrees HPT were analyzed prospectively. Based on surgeon-performed ultrasound (US) and sestamibi scan (MIBI), LE was initially performed. Regardless of results, BE followed to identify the presence of additional parathyroid pathology.
Of 1158 patients, 242 (21%) were found to require concomitant thyroid surgery thus excluding LE. Of the remaining 916 patients, a single abnormal gland was identified on MIBI in 682 (74%), US in 731 (80%), and concordance of both in 588 (64%). Unsuspected multiglandular disease (MGD) was identified at BE in 22%, 22%, and 20% of patients, respectively. Adding intraoperative parathyroid hormone sampling (IOPTH) further reduced the rate of unsuspected MGD to 16%, 17%, and 16%. Overall, IOPTH correctly predicted MGD in only 22%. Neither concomitant nonsurgical thyroid disease nor more stringent selection criteria (preop Ca>11 mg/dL and PTH>120 pg/dL) altered success rates. In patients with MGD, a subsequent gland identified was larger than the index gland in 23%. Ninety-eight percent of BE patients were cured of 1 degrees HPT.
This is the largest study to evaluate the prevalence of additional parathyroid pathology in patients who are candidates for LE. Limitations in localizing studies and IOPTH fail to identify MGD in at least 16% of patients, risking future recurrence.
本研究旨在确定有限颈部探查(LE)治疗原发性甲状旁腺功能亢进症(1°HPT)的成功率。
1999年至2007年间,1407例甲状旁腺功能亢进症患者接受了双侧颈部探查(BE)。其中,对1158例首次发生散发性1°HPT的患者进行了前瞻性分析。基于外科医生进行的超声(US)和锝[99mTc]甲氧基异丁基异腈扫描(MIBI),最初进行LE。无论结果如何,随后进行BE以确定是否存在额外的甲状旁腺病变。
在1158例患者中,发现242例(21%)需要同时进行甲状腺手术,因此排除LE。在其余916例患者中,MIBI发现单个异常腺体的有682例(74%),US发现的有731例(80%),两者一致的有588例(64%)。在BE时分别有22%、22%和20%的患者被发现存在未被怀疑的多腺体疾病(MGD)。增加术中甲状旁腺激素采样(IOPTH)进一步将未被怀疑的MGD发生率降低至16%、17%和16%。总体而言,IOPTH仅能正确预测22%的MGD。同时存在的非手术性甲状腺疾病和更严格的选择标准(术前血钙>11mg/dL和甲状旁腺激素>120pg/dL)均未改变成功率。在MGD患者中,随后发现的腺体比索引腺体大的占23%。98%的BE患者的1°HPT得到治愈。
这是评估LE候选患者中额外甲状旁腺病变患病率的最大规模研究。定位研究和IOPTH的局限性导致至少16%的患者未能识别出MGD,存在未来复发的风险。